Ministry of Health urgently recalls dangerous drug - details

The Israeli Ministry of Health has approved the recall of Johnson & Johnson's IMAAVY drug due to the risk of glass particles in certain batches. The medication is used to treat myasthenia gravis. A level two measure: medical institutions are instructed to stop use, isolate stocks, and return the drug to the distributor.

The Israeli Ministry of Health has approved an urgent recall of the drug IMAAVY (Johnson & Johnson) due to the risk of glass particles in certain batches, which may form during the production stage. The level two measure applies to specific batches supplied to medical institutions. The Ministry of Health ordered the cessation of use, isolation of existing stocks, and return of the drug to the distributor SLA for a monetary credit. IMAAVY is used to treat generalized myasthenia gravis in adults and adolescents aged 12 and older with antibodies to acetylcholine receptors or muscle-specific tyrosine kinase. The main risk is the entry of tiny glass particles into the vascular system. Ministry of Health specialists note that the discontinuation of certain batches should not lead to a drug shortage in Israel. The article also mentions previous warnings from the Ministry of Health about the weight loss drug G-Slim and the drug Sabril.